ISRCTN06452574 https://doi.org/10.1186/ISRCTN06452574

New therapeutic targets in stroke prevention: the effects of allopurinol on the cerebrovasculature of patients with subcortical stroke

Submission date
09/09/2005

Registration date
22/11/2005

Last Edited
01/02/2010

Recruitment status
No longer recruiting

Overall study status
Completed

Condition category
Circulatory System

[_] Prospectively registered
[_] Protocol
[_] Statistical analysis plan
[X] Results
[_] Individual participant data

Plain English summary of protocol
Not provided at time of registration

Contact information

Type(s)
Scientific

Contact name
Dr Matthew Walters

Contact details
Department of Medicine & Therapeutics
Western Infirmary
44 Church Street
Glasgow
United Kingdom
G11 6NT
+44 (0)141 211 2821
gcl203@clinmed.gla.ac.uk

Additional identifiers

Protocol serial number
N/A

Study information

Scientific Title

Study objectives
Treatment with xanthine oxydase inhibitor allopurinol will improve cerebrovascular reactivity in patients with subcortical stroke.

Ethics approval required
Old ethics approval format

Ethics approval(s)
Not provided at time of registration

Study design
Randomised controlled trial

Primary study design
Interventional

Study type(s)
Treatment

Health condition(s) or problem(s) studied
Subcortical stroke.

Interventions
3 month allopurinol treatment (300 mg) versus lactose tablet.

Intervention Type
Drug

Phase
Not Specified

Drug/device/biological/vaccine name(s)
Allopurinol

Primary outcome(s)
The change in flow velocity in the middle cerebral artery (MCA) following acetazolomide infusion.

Key secondary outcome(s))
1. Change in serum urate
2. Recurrent stroke or other cardiac event

Completion date
01/11/2007

Eligibility

Key inclusion criteria
1. Subcortical stroke
2. Index stroke within 2 weeks and 3 months prior to randomisation

Participant type(s)
Patient

Healthy volunteers allowed
No

Age group
Adult

Sex
All

Key exclusion criteria
1. >70% Internal carotid artery stenosis
2. Coronary artery disease
3. Other significant comorbidity
4. Contraindication to allopurinol
5. Contraindication to acetazolamide
6. Concurrent azathioprine or 6-mercaptopurine therapy
7. Serum creatinine >250 µmol/l
8. Woman of childbearing potential

Date of first enrolment
01/11/2005

Date of final enrolment
01/11/2007

Locations

Countries of recruitment
United Kingdom

Scotland

Study participating centre
Department of Medicine & Therapeutics
Glasgow
United Kingdom
G11 6NT

Sponsor information

Organisation
Greater Glasgow NHS Board/Glasgow University (UK)

ROR
https://ror.org/05kdz4d87

Funder(s)

Funder type
Charity

Funder Name
West Endowment Fund (UK)

Results and Publications

Individual participant data (IPD) sharing plan

IPD sharing plan summary
Not provided at time of registration

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Results article	results	01/11/2009		Yes	No